View : 784 Download: 0
Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model
- Title
- Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model
- Authors
- Bae, Ji Yun; Jun, Kang Il; Kang, Chang Kyung; Song, Kyoung-Ho; Choe, Pyoeng Gyun; Bang, Ji-Hwan; Kim, Eu Suk; Park, Sang Won; Kim, Hong Bin; Kim, Nam-Joong; Park, Wan Beom; Oh, Myoung-don
- Ewha Authors
- 배지윤
- SCOPUS Author ID
- 배지윤
- Issue Date
- 2019
- Journal Title
- ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ISSN
- 0066-4804
1098-6596
- Citation
- ANTIMICROBIAL AGENTS AND CHEMOTHERAPY vol. 63, no. 4
- Keywords
- SAL200; Staphylococcus aureus; mice; phage endolysin; pneumonia
- Publisher
- AMER SOC MICROBIOLOGY
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- SAL200 is derived from a phage endolysin and is a novel candidate drug for the treatment of Staphylococcus aureus infection. We investigated the efficacy of the recombinant endolysin SAL200 in a lethal murine pneumonia model. Lethal pneumonia was established by intranasally administering a methicillin-susceptible (Newman) or methicillin-resistant (LAC) S. aureus strain into BALB/c mice. The mice were treated with a single intranasal administration of SAL200 or phosphate-buffered saline at 2 h after S. aureus infection. The survival rates were recorded until 60 h after the bacterial challenge. The bacterial loads in the lungs and blood, histopathology of lung tissues, and serum cytokine levels were evaluated following the S. aureus challenge. The SAL200-treated group and control group exhibited 90% to 95% and 10% to 40% survival rates, respectively. The bacterial loads in the lungs of the SAL200-treated group were significantly lower by similar to 10-fold than those of the control group as early as 1 h after treatment. Histopathologic recovery of pneumonia was observed in the SAL200-treated mice. The cytokine levels were comparable between groups. These results suggest that direct administration of SAL200 into the lungs could be a potential adjunct treatment against severe pneumonia caused by S. aureus.
- DOI
- 10.1128/AAC.02009-18
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML